Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT02079844
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Phase 4
Completed
- Conditions
- Essential Hypertension Complicated by Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 33
- Registration Number
- NCT02079805
Phase III Study of Intramuscular TAK-816 in Healthy Infants
Phase 3
Completed
- Conditions
- Healthy VolunteersHaemophilus Influenzae Type b, Prevention
- Interventions
- Biological: TAK-816
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 31
- Registration Number
- NCT02074345
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Phase 2
Completed
- Conditions
- Grade I or II Essential Hypertension
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 353
- Registration Number
- NCT02072330
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT02068443
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1067
- Registration Number
- NCT02068508
Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3409
- Registration Number
- NCT02068495
Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Phase 1
Completed
- Conditions
- Bioavailability
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT02064907
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
Phase 2
Completed
- Conditions
- Involutional Osteoporosis
- Interventions
- Drug: NE-58095 IR PlaceboDrug: NE-58095 IRDrug: NE-58095 DRDrug: NE-58095 DR Placebo
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 871
- Registration Number
- NCT02063854
Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3339
- Registration Number
- NCT02058992
© Copyright 2025. All Rights Reserved by MedPath